Austin Nakatsuka, MD
Ophthalmology · Salt Lake City, UTNPI 1366821688
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by NEW World Medical,inc. at 40.6% of the total. Reporting peaked in 2024 at $15,574 and has fallen 60.2% since, to $6,203 in 2025. Among ophthalmology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $277.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$11K
- Glaukos Corporation$6K
- Sight Sciences, Inc.$5K
- Alcon$2K
- W. L. Gore & Associates, Inc.$1K
- AbbVie$756
- plus $906 from 7 others
What the payments were for
- Consulting fees$6,46524%
- Speaking & faculty fees$11,50043%
- Travel & lodging$3,14812%
- Food & beverage$4,78718%
- Other$1,0394%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 37 | $10,944 |
| Glaukos Corporation | 4 | $6,273 |
| Sight Sciences, Inc. | 15 | $5,101 |
| Alcon | 21 | $1,813 |
| W. L. Gore & Associates, Inc. | 2 | $1,146 |
| AbbVie(2 entities) | 8 | $756 |
| Nova Eye, Inc. | 1 | $234 |
| Novartis | 1 | $124 |
| Bausch & Lomb Americas Inc. | 1 | $124 |
| Carl Zeiss Meditec USA, Inc. | 1 | $118 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $105 |
| Aerie Pharmaceuticals, Inc. | 1 | $102 |
| Sun Pharmaceutical Industries Inc. | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$8,252
- Ahmed Glaucoma Valve$8,252
- Clearpath$8,050
- Streamline$8,050
- OMNI(R) SURGICAL SYSTEM (US)$4,694
- Via360$3,777
- Product in Development$1,140
- Voyager DSLT$1,039
- XEN GLAUCOMA TREATMENT SYSTEM$318
- Streamline Surgical System$202
- PanOptix$138
- Humira$120
- QUATERA 700$118
- Clareon$106
- iStent inject Trabecular Micro-Bypass Stent System$104
- Rocklatan$102
- Rhopressa$102
How this compares
$26,939 in reported general payments places this provider in the 95th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 29 | $9,405 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $7,384 |
| Latanoprost | 436 | $5,721 |
| Prednisolone Acetate | 107 | $4,440 |
| Ofloxacin | 328 | $4,003 |
| Brimonidine Tartrate | 157 | $2,719 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 189 | $2,327 |
| Timolol Maleate | 141 | $1,869 |
| Ketorolac Tromethamine | 51 | $1,399 |
| MoxifloxacinMoxifloxacin Hcl | 24 | $899 |
| Dorzolamide Hcl | 45 | $843 |
| Dexamethasone Sodium PhosphateDexamethasone Sodium Phosp/Pf | 104 | $713 |
| Acetazolamide ErAcetazolamide | 44 | $650 |
| Doxycycline Hyclate | 21 | $522 |
| ErythromycinErythromycin Base | 20 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan | $756 | $16,78947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
- Amy LinSalt Lake City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.